as nasdaq copenhagen gen industry biotechnology founded 1999 headquarters copenhagen denmark key people jan van de winkel president and ceo mats pettersson chairman products arzerra revenue dkk 664 million 2013 1 operating income dkk 69.3 million 2013 1 profit dkk 112.4 million 2013 1 number of employees 157 2013 1 website www.genmab.com genmab a s is a danish biotechnology company founded in february 1999 by florian sch nharting at the time managing director of bankinvest biomedical venture fund . 2 genmab is based in copenhagen . internationally it operates through the subsidiaries genmab bv in utrecht the netherlands and genmab inc in princeton new jersey usa . the company is publicly traded on the nasdaq omx copenhagen a s. 3 the company has two approved antibodies arzerra ofatumumab for the treatment of certain chronic lymphocytic leukemia indications and darzalex daratumumab for the treatment of heavily pretreated or double refractory multiple myeloma . daratumumab is in clinical development for additional multiple myeloma indications and for non hodgkin s lymphoma . they also have a broad clinical and pre clinical product pipeline . 4 contents 1 technology 2 history of the company 3 partnerships 4 clinical pipeline 5 references 6 external links technology edit genmab s technology is licensed from medarex to create fully human high affinity antibodies using transgenic mice . these antibodies are less likely to elicit an allergic reaction and other side effects compared with other types of man made antibodies containing other animal proteins because the igg antibodies produced have human proteins . this technology is called the humab mouse technology . one benefit of using this type of technology is that there is no need for humanization or complicated genetic engineering to make this antibody fit for humans which cuts down on expenses and time spent developing it . it can be generated within months and can be selected to bind to specific antigens such as tumor cells and other infectious agents . genmab also has developed its own technology called unibody which is used to make smaller antibodies in contrast to the traditional full sized monoclonal antibody . its smaller size allows for better distribution over larger target areas like tumors . the unibody can only bind to one site and doesn t elicit a harmful immune response by binding to two sites and over activating cell growth . it does not kill target cells but rather silences or inhibits them . thus it can be used to treat certain cancers inflammations allergies and asthmas where killing the cell isn t the objective . 5 the technology modifies the human igg4 antibody . normally the igg4 is considered inert and doesn t elicit an immune response . however they are also unstable and fall apart easily which makes them unsuitable for therapeutic use . genmab changes the shape of the igg4 antibody by eliminating the hinge the part of the antibody that creates the y shape . this halves the antibody creating a smaller version now known as their unibody . this smaller version can only bind to one site and does not stimulate cancer cells to grow . 6 history of the company edit founder of genmab florian sch nharting genmab was founded as a european spin off of american biotech company medarex in february 1999 . danish investment firm bankinvest under florian sch nharting provided the seed investment for the company to start up in copenhagen . lisa drakeman a vice president at medarex and wife of donald drakeman medarex s ceo and president at the time was appointed ceo of genmab upon incorporation . like medarex genmab began work producing monoclonal antibodies for life threatening or debilitating diseases . rising quickly in the biotech world genmab attracted many investors especially venture capital firms . the company went public in october 2000 earning 1.56 billion danish kroner and had a second public offering in january 2006 yielding 800 million kroner . that same year genmab also had a licensing agreement with glaxosmithkline worth 1.6 billion for the antibody ofatumumab . besides gsk genmab also has licensing deals with amgen roche and lundbeck involving therapeutic monoclonal antibodies with multiple indications . in 2005 the biotechnology industry organization bio and the long island life sciences initiative 7 honored genmab with a james d. watson helix award . 8 the company s first product arzerra ofatumumab reached the us market in 2009 for refractory chronic lymphocytic leukemia . 9 in 2010 jan van de winkel was appointed as president and chief executive officer of genmab . previously he was president research & development and chief scientific officer and he has over 20 years of experience in the therapeutic antibody field and served as vice president and scientific director of medarex europe prior to genmab . he is the author of over 300 scientific publications and has been responsible for over 40 patents and pending patent applications . 10 partnerships edit amgen in may 1999 genmab entered a sub license agreement with amgen where it would gain rights to the il15 antibodies . in october 2001 this was replaced by a direct license agreement where amgen retained exclusive commercialization options for the products through phase ii . amgen has also expanded its agreement to a new antibody program targeting additional disease targets . amgen has discontinued development of the il15 antibody amg 714 in psoriasis and rheumatoid arthritis based on disappointing results from recent clinical studies . amgen is exploring options to maximize the value of this asset but as this time no further internal development of a lead indication is planned . glaxosmithkline in december 2006 genmab entered a deal with glaxosmithkline to co develop and commercialize ofatumumab which is a drug that could be used for treatment in cd20 positive b cell chronic lymphocytic leukemia follicular non hodgkin s lymphoma rheumatoid arthritis and other indications . the agreement gave genmab a license fee of dkk 582 million and gsk bought 4 471 202 shares of genmab for 2 033 million . the potential value of this agreement could be 12.0 billion dkk if all milestones are reached and commercial success is reached in the fields of cancer autoimmune and inflammatory disease . until 2008 genmab will bear the entire development cost after which the costs will be shared equally between the two . genmab and gsk amended the agreement in july 2010 . gsk has taken responsibility for developing ofatumumab in autoimmune indications while continuing to jointly develop ofatumumab with genmab in oncology indications . genmab received an up front payment of gbp 90 million from gsk in relation to the amendment and the company s future funding commitment is capped at gbp 145 million . further milestones due to genmab under the oncology development program will be reduced by 50 % . gsk is now solely responsible for funding development in autoimmune indications and genmab will forgo development milestones for autoimmune indications and the first two sales milestones . in addition genmab has collaborations with roche rg1507 a monoclonal antibody directed against igf 1r collaboration was terminated in 2009 11 lundbeck and seattle genetics . clinical pipeline edit status of genmab s clinical pipeline as of november 2015 . product disease indications phase partner daratumumab multiple myeloma approved j & j ofatumumab 20 studies chronic lymphocytic leukemia cll approved gsk ofatumumab follicular lymphoma fl iii gsk ofatumumab diffuse large b cell lymphoma dblcl iii gsk ofatumumab pemphigus vulgaris pv iii gsk ofatumumab relapsing remitting multiple sclerosis rrms ii gsk ofatumumab waldenstrom s macroglobulinemia wm ii gsk humax tf adc cancer i seattle genetics teprotumumab active thyroid eye disease ii river vision teprotumumab diabetic macular edema i river vision references edit a b c d annual report 2013 . genmab . retrieved 2014 05 20 . http www.sec.gov archives edgar data 874255 0000950130 99 001225 . txt microsite gen genmab dk0010272202 . nasdaq omx nordic . retrieved 2014 01 02 . about us . www.genmab.com . retrieved 2016 07 14 . 1 2 www.lilsi.org . www.lilsi.org . retrieved 2014 01 02 . http www.bio.org news pressreleases newsitem.asp id 2005 0224 01 3 genmab jan van de winkel . www.genmab.com . retrieved 2016 07 14 . john carroll 2009 12 07 . genmab shares slide after roche dumps collaboration . fiercebiotech . retrieved 2016 05 02 . external links edit official website v t e omx copenhagen 20 companies of denmark march 2016 a.p. m ller m rsk carlsberg chr . hansen coloplast danske bank dsv flsmidth & co. genmab gn store nord iss jyske bank nordea novo nordisk novozymes pandora tdc tryg vestas wind systems william demant retrieved from https en.wikipedia.org w index.php title genmab & oldid 735974465 categories pharmaceutical companies of denmarkbiotechnology companies of denmarklife science companies based in copenhagenpharmaceutical companies established in 1999danish brands navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page print export create a bookdownload as pdfprintable version languages danskportugu s suomisvenska edit links this page was last modified on 24 august 2016 at 09 13 . text is available under the creative commons attribution sharealike license ; additional terms may apply . by using this site you agree to the terms of use and privacy policy . wikipedia is a registered trademark of the wikimedia foundation inc. a non profit organization . privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view